| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
56.72
|
|
2
|
Standardisation of spirometry.
|
Eur Respir J
|
2005
|
48.20
|
|
3
|
Interpretative strategies for lung function tests.
|
Eur Respir J
|
2005
|
21.50
|
|
4
|
Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.
|
Eur Respir J Suppl
|
1993
|
20.55
|
|
5
|
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.
|
Am J Respir Crit Care Med
|
2009
|
9.38
|
|
6
|
Development and validation of a questionnaire to measure asthma control.
|
Eur Respir J
|
1999
|
9.35
|
|
7
|
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
|
Chest
|
2006
|
8.43
|
|
8
|
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
|
Ann Intern Med
|
2007
|
5.51
|
|
9
|
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
|
N Engl J Med
|
2016
|
4.51
|
|
10
|
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone.
|
N Engl J Med
|
2016
|
3.93
|
|
11
|
Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.
|
Respir Med
|
2005
|
3.48
|
|
12
|
COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity.
|
Chest
|
2002
|
3.34
|
|
13
|
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
|
Thorax
|
2010
|
2.79
|
|
14
|
Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.
|
N Engl J Med
|
2016
|
2.65
|
|
15
|
Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study.
|
Chest
|
2009
|
2.65
|
|
16
|
Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies.
|
Thorax
|
2011
|
2.59
|
|
17
|
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.
|
Cochrane Database Syst Rev
|
2014
|
2.41
|
|
18
|
Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
|
Am J Respir Crit Care Med
|
2001
|
2.32
|
|
19
|
Tiotropium versus placebo for chronic obstructive pulmonary disease.
|
Cochrane Database Syst Rev
|
2012
|
2.21
|
|
20
|
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.
|
Chest
|
2009
|
2.20
|
|
21
|
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
|
Lancet
|
2016
|
2.19
|
|
22
|
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
|
Eur Respir J
|
2009
|
2.11
|
|
23
|
The FDA and safe use of long-acting beta-agonists in the treatment of asthma.
|
N Engl J Med
|
2010
|
2.02
|
|
24
|
The efficiency of simulation-based multiple comparisons.
|
Biometrics
|
1987
|
1.91
|
|
25
|
Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma.
|
N Engl J Med
|
2011
|
1.91
|
|
26
|
Risks of long-acting beta-agonists in achieving asthma control.
|
N Engl J Med
|
2009
|
1.89
|
|
27
|
Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.
|
Chest
|
2005
|
1.83
|
|
28
|
The local side effects of inhaled corticosteroids: current understanding and review of the literature.
|
Chest
|
2004
|
1.76
|
|
29
|
Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis.
|
Ann Allergy Asthma Immunol
|
2007
|
1.74
|
|
30
|
Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.
|
Chest
|
2002
|
1.73
|
|
31
|
Inhaled corticosteroids and the risks of diabetes onset and progression.
|
Am J Med
|
2010
|
1.66
|
|
32
|
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
|
Thorax
|
2015
|
1.55
|
|
33
|
Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis.
|
Thorax
|
2012
|
1.48
|
|
34
|
Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
|
Thorax
|
2008
|
1.47
|
|
35
|
A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
|
Ann Allergy Asthma Immunol
|
2001
|
1.45
|
|
36
|
Inhaled corticosteroids for stable chronic obstructive pulmonary disease.
|
Cochrane Database Syst Rev
|
2012
|
1.38
|
|
37
|
Use of inhaled and oral corticosteroids and the long-term risk of cataract.
|
Ophthalmology
|
2009
|
1.13
|
|
38
|
Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010.
|
Respir Res
|
2013
|
1.13
|
|
39
|
Smoking cessation and COPD.
|
Eur Respir Rev
|
2013
|
1.09
|
|
40
|
Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.
|
Drugs
|
2012
|
1.09
|
|
41
|
Long-acting beta2-agonists for chronic obstructive pulmonary disease.
|
Cochrane Database Syst Rev
|
2013
|
1.07
|
|
42
|
Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
|
Respir Med
|
2011
|
1.05
|
|
43
|
Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population.
|
Am Rev Respir Dis
|
1991
|
1.02
|
|
44
|
Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients.
|
Int J Chron Obstruct Pulmon Dis
|
2008
|
1.01
|
|
45
|
Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis.
|
Int J Chron Obstruct Pulmon Dis
|
2013
|
1.01
|
|
46
|
Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients.
|
Respir Med
|
2008
|
0.92
|
|
47
|
Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II.
|
Chest
|
2004
|
0.89
|
|
48
|
Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler.
|
Eur Respir J
|
2002
|
0.87
|
|
49
|
Risk of mortality associated with formoterol: a systematic review and meta-analysis.
|
Eur Respir J
|
2009
|
0.87
|
|
50
|
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.
|
COPD
|
2015
|
0.87
|
|
51
|
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.
|
Ann Am Thorac Soc
|
2015
|
0.85
|
|
52
|
A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
|
BMC Pulm Med
|
2012
|
0.85
|
|
53
|
Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database.
|
Int J Chron Obstruct Pulmon Dis
|
2011
|
0.81
|
|
54
|
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
|
COPD
|
2015
|
0.81
|
|
55
|
Nebulized formoterol fumarate: Dose selection and pharmacokinetics.
|
Pulm Pharmacol Ther
|
2008
|
0.80
|
|
56
|
Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
|
Br J Clin Pharmacol
|
2004
|
0.78
|
|
57
|
Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.
|
J Asthma
|
2003
|
0.78
|
|
58
|
A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
|
Respiration
|
2005
|
0.78
|
|
59
|
A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
|
Respiration
|
2005
|
0.77
|
|
60
|
Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
|
Lancet Respir Med
|
2016
|
0.76
|
|
61
|
Smoking cessation for people with chronic obstructive pulmonary disease.
|
Cochrane Database Syst Rev
|
2016
|
0.76
|
|
62
|
Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement.
|
Respir Med
|
2015
|
0.75
|